下一代益生菌对代谢功能障碍相关的脂肪性肝病的影响:一个并行,双盲,随机,安慰剂控制的试验
Sung-Min Won1, Hyunchae Joung2, In Gyu Park1
1Institute for Liver and Digestive Diseases, Hallym University College of Medicine, Chuncheon, Republic of Korea.
Journal of translational medicine
|December 10, 2025
概括
下一代益生菌改善了肝功能,并改变了代谢功能障碍相关的脂肪性肝病 (MASLD) 患者的肠道微生物组合. 补充导致关键细菌群体和生物化学标记物的显著变化.
科学领域:
- 胃肠病学和肝病学
- 微生物组研究 微生物组研究
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 与肠道微生物群失调有关.
- 下一代益生菌,包括Lactobacillus delbrueckii亚种. 乳球菌 (LL001),L. helveticus (LH001) 和Pediococcus pentosaceus KID7 (PPKID7) 被研究了它们对MASLD的影响.
- 这项研究旨在评估这些益生菌对MASLD患者肝功能和肠道微生物群的影响.
研究的目的:
- 评估特定下一代益生菌在改善MASLD患者肝功能参数方面的疗效.
- 研究益生菌补充剂对患有MASLD的个体肠道微生物组合的影响.
- 确定益生菌摄入量与血清生物化学标记物和便微生物概况变化之间的关联.
主要方法:
- 这是一项双盲并行试验,涉及110名MASLD患者.
- 随机分配到四组:三种益生菌配方 (LL001,LH001,PPKID7) 或安慰剂,与西利马林一起服用8周.
- 在基线和终点收集临床数据,血清和便样本用于16S rRNA基因测序.
主要成果:
- 补充LL001显著降低了氨酸转氨酶和酸转氨酶水平.
- 摄入LH001与体重显著减少有关,而PPKID7降低了胆固醇水平.
- 益生菌治疗改变了肠道微生物群,减少了蛋白质细菌,增加了鲁米诺可可科科和拉克诺斯皮拉科;观察到趋势是增加了Bifidobacterium.
结论:
- 用LL001,LH001和PPKID7益生菌补充八周,在MASLD患者中显示出有益的效果.
- 益生菌摄入与肝功能测试的显著改善和肠道微生物组合的有利转变有关.
- 这些发现表明,下一代益生菌可能是管理MASLD的有价值的治疗策略.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
192
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
192
01:29Chronic Pancreatitis II: Collaborative Care
286
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
286